Company: OSRH
Filing Date: 2025-05-28
Form Type: S-1
Source: 0001213900-25-048346
Chunk: 20

Company: OSR Holdings, Inc.
Filing Date: 2025-05-28
Form: S-1
Chunk 20
---
 candidates that obtain marketing approval. We currently do not have marketing and sales management operations for any of our pharmaceutical products and will rely, at least initially, on third parties for support. The responsibilities of marketing operations would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. We will reevaluate the sales operations from time to time and may eventually build an in-house marketing and sales management organization. Our Key Team Leaders Our company is led by Kuk Hyoun Hwang, our President and Chief Executive Officer, Dr. Constance Höfer, our Chief Scientific Officer, Jun Chul Whang, our Chief Legal Officer and Secretary, Gihyoun Bang, the Chief Financial Officer and Sang Hoon Kim, the Head of Corporate Venture Capital. Dr. Höfer is a seasoned leader in drug development with more than 20 years of experience in oncology and immunology. The group of executives leading OSR Holdings combine deep scientific, legal, and financial expertise to advance what we believe are transformative therapies and healthcare solutions. 11

Summary of Risk Factors Our business, our business sector and investing in our securities involve a number of risks of which you should be aware before making an investment decision. You should read this summary together with the description of each risk factor contained in the “ Risk Factors” section of this Form S-1, as well as other documents filed from time to time with the SEC, for a more detailed discussion of certain risks that could materially adversely affect our financial conditions and the market price of our securities. The following list describes some of the principal risk factors applicable to the Company and our subsidiaries.

| ● | We require substantial additional funding to meet our financial                                                                      
 needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce, or  
 altogether cease our current and future product development programs, future acquisitions and other commercialization efforts. Our   
 previously agreed and anticipated $20 million PIPE (Private Investment in Public Equity) transaction was cancelled by the            
 investor due to macroeconomic factors specific to Korea. As a result, the Company did not receive the anticipated amount of cash at  
 the February 2025 closing of our initial business combination and the Company was insolvent as of such closing date and lacked       
 sufficient cash to fund its operations or pay its outstanding expenses and debts. The Company has entered into agreements for        
 alternative financing (including the ELOC facility that is the subject of this registration statement), but there is no guar